Publishing of Nexstim Plc 2015 Full Year Results

Helsinki, 11 February 2016 at 9:00 a.m.

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, will announce its full year results for the year ended 31 December 2015 in the afternoon of Monday 29 February 2016.

A conference call for analysts, investors and media will take place at 16:00 EET on Monday 29 February 2016, hosted by Janne Huhtala, Chief Executive Officer, and Mikko Karvinen, Chief Financial Officer, who will present the financial and operational results followed by a Q&A session. The presentation material will be available on the Nexstim website shortly before the conference call begins.

The dial-in numbers for the conference call are:

Finland: +358 (0) 800112363
Sweden: +46 (0) 850336434
UK: +44 (0) 8006940257
US: +1 (1) 6315107498

Standard International: +44 (0) 1452 555566

The call ID number is 47933395

NEXSTIM PLC
Janne Huhtala, Chief Executive Officer

For further information please visit www.nexstim.com or contact:

Nexstim +358 (0)40 8615046
Janne Huhtala, Chief Executive Officer janne.huhtala@nexstim.com

UB Securities Ltd (Certified Adviser) +358 (0)9 2538 0246

Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton nexstim@consilium-comms.com

About Nexstim Plc
Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and

Nasdaq First North Sweden. In H2 2015, the Company received a recommendation from the Data Safety Monitoring Board (DSMB) to continue the Phase III stroke therapy NICHE trial without any modifications. The first interim analysis on the NICHE (Navigated Inhibitory rTMS to Contralesional Hemisphere) trial using NBT® was performed after 81 patients reached their primary safety outcome assessment, on track, at six months post-treatment. For more information please visit www.nexstim.com.